Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Abstract Objectives Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tum...
Main Authors: | Javier Sánchez Ramírez, Mónica Bequet-Romero, Yanelys Morera Díaz, Francisco Hernández-Bernal, Marta Ayala Avila |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13104-019-4368-z |
Similar Items
-
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants
by: Javier Sánchez Ramírez, et al.
Published: (2017-07-01) -
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program
by: Javier Sánchez Ramírez, et al.
Published: (2020-03-01) -
Role of VEGF and VEGF Receptors in the Glomerulus
by: Sison, Karen Tanya
Published: (2009) -
Role of VEGF and VEGF Receptors in the Glomerulus
by: Sison, Karen Tanya
Published: (2009) -
Proteolytic Cleavages in the VEGF Family: Generating Diversity Among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs
by: Jaana Künnapuu, et al.
Published: (2021-02-01)